Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 1
2006 3
2007 1
2008 2
2009 6
2010 1
2011 1
2012 2
2013 2
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine.
Herzog C, Hartmann K, Künzi V, Kürsteiner O, Mischler R, Lazar H, Glück R. Herzog C, et al. Vaccine. 2009 Jul 16;27(33):4381-7. doi: 10.1016/j.vaccine.2009.05.029. Epub 2009 May 29. Vaccine. 2009. PMID: 19450630 Review.
.), has sold over 41 million doses worldwide of the virosomal adjuvanted influenza vaccine, Inflexal V. Since 1992, 29 company sponsored clinical studies investigating the efficacy and safety of Inflexal V have been completed in which 3920 subjects par …
.), has sold over 41 million doses worldwide of the virosomal adjuvanted influenza vaccine, Inflexal V. Since 1992, 29 company …
Inflexal V a trivalent virosome subunit influenza vaccine: production.
Mischler R, Metcalfe IC. Mischler R, et al. Vaccine. 2002 Dec 20;20 Suppl 5:B17-23. doi: 10.1016/s0264-410x(02)00512-1. Vaccine. 2002. PMID: 12477413
Inflexal V, a novel virosome-based trivalent influenza vaccine, has been shown to be highly immunogenic and well tolerated in children, young adults, and the elderly. Here we discuss the techniques for the manufacture of Inflexal V, highlighting the pu …
Inflexal V, a novel virosome-based trivalent influenza vaccine, has been shown to be highly immunogenic and well tolerated in …
Inflexal V--the influenza vaccine with the lowest ovalbumin content.
Kürsteiner O, Moser C, Lazar H, Durrer P. Kürsteiner O, et al. Vaccine. 2006 Nov 10;24(44-46):6632-5. doi: 10.1016/j.vaccine.2006.05.084. Epub 2006 Jun 12. Vaccine. 2006. PMID: 16828206
Comparing several influenza vaccines present on the market, ELISA and Western blot analysis showed clearly a very low level of ovalbumin in Inflexal V. Furthermore, data showed, that Inflexal V is the influenza vaccine with the lowest ovalbumin content …
Comparing several influenza vaccines present on the market, ELISA and Western blot analysis showed clearly a very low level of ovalbumin in …
Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V and Fluad ) in preventing hospitalization for influenza and pneumonia in the elderly: a matched case-control study.
Gasparini R, Amicizia D, Lai PL, Rossi S, Panatto D. Gasparini R, et al. Hum Vaccin Immunother. 2013 Jan;9(1):144-52. doi: 10.4161/hv.22231. Epub 2012 Nov 10. Hum Vaccin Immunother. 2013. PMID: 23143775 Free PMC article.
The adjuvanted influenza vaccines (Fluad () considered together with Inflexal V () ) were associated with a significant reduction in the risk of hospitalization, their effectiveness being 94.8% (CI 77.1-98.8). Adjusted vaccine effectiveness was 95.2% (CI 62.8-99.4) …
The adjuvanted influenza vaccines (Fluad () considered together with Inflexal V () ) were associated with a significant reduct …
Safe vaccination of children with a virosomal adjuvanted influenza vaccine.
Künzi V, Dornseiff M, Horwath J, Hartmann K. Künzi V, et al. Vaccine. 2009 Feb 18;27(8):1261-5. doi: 10.1016/j.vaccine.2008.12.008. Epub 2008 Dec 27. Vaccine. 2009. PMID: 19114080 Clinical Trial.
A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influenza vaccine Inflexal V (in Germany marketed as Infectovac Flu). Children aged 6 months to 6 years received one or two doses. .. …
A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influen …
New technology platforms in the development of vaccines for the future.
Glück R, Metcalfe IC. Glück R, et al. Vaccine. 2002 Dec 20;20 Suppl 5:B10-6. doi: 10.1016/s0264-410x(02)00513-3. Vaccine. 2002. PMID: 12477412 Review.
Particular attention is paid to the currently licensed Epaxal and Inflexal V, good examples of the improvements being made in vaccinology. ...
Particular attention is paid to the currently licensed Epaxal and Inflexal V, good examples of the improvements being made in …
Virosomal adjuvanted antigen delivery systems.
Moser C, Metcalfe IC, Viret JF. Moser C, et al. Expert Rev Vaccines. 2003 Apr;2(2):189-96. doi: 10.1586/14760584.2.2.189. Expert Rev Vaccines. 2003. PMID: 12899570 Review.
A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly.
Levin Y, Kochba E, Shukarev G, Rusch S, Herrera-Taracena G, van Damme P. Levin Y, et al. Vaccine. 2016 Oct 17;34(44):5262-5272. doi: 10.1016/j.vaccine.2016.09.008. Epub 2016 Sep 22. Vaccine. 2016. PMID: 27667332 Free article. Clinical Trial.
METHODS: A total of 370 healthy participants (65years) were randomized equally 1:1:1:1:1:1 to six influenza vaccine treatments (approximately 60-63 participants per treatment arm) at day 1 that consisted of three investigational virosomal vaccine formulations at doses of 7.5, 15, …
METHODS: A total of 370 healthy participants (65years) were randomized equally 1:1:1:1:1:1 to six influenza vaccine treatments (approximatel …
Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy.
Esposito S, Gasparini C, Martelli A, Zenga A, Tremolati E, Varin E, Marseglia GL, Fiocchi A, Principi N. Esposito S, et al. Vaccine. 2008 Aug 26;26(36):4664-8. doi: 10.1016/j.vaccine.2008.06.095. Epub 2008 Jul 17. Vaccine. 2008. PMID: 18639601 Clinical Trial.
They were then vaccinated with the whole dose of Inflexal V intramuscularly in a one-dose protocol, and the occurrence of any immediate or delayed adverse events were actively monitored for 28 days. The results showed the safety of the administration, and demonstrat …
They were then vaccinated with the whole dose of Inflexal V intramuscularly in a one-dose protocol, and the occurrence of any …
Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
Zuccotti G, Amendola A, Viganò A, Pariani E, Zappa A, Pogliani L, Giacomet V, Savarino A, Podestà A, Rottoli A, Tanzi E, Zanetti A, Radaelli G. Zuccotti G, et al. Vaccine. 2007 Sep 17;25(37-38):6692-8. doi: 10.1016/j.vaccine.2007.07.013. Epub 2007 Jul 27. Vaccine. 2007. PMID: 17697730
A single dose (0.5 ml) of a virosomal subunit inactivated influenza vaccine (Inflexal V) was injected in 106 asthmatic children aged 3-9 years. ...
A single dose (0.5 ml) of a virosomal subunit inactivated influenza vaccine (Inflexal V) was injected in 106 asthmatic childre …
21 results